18F-Sodium Fluoride Positron Emission Tomography in Cardiac Disease
Despite the recent advances, cardiovascular disease remains the leading cause of death worldwide. There is a need to improve targeting of existing novel diagnostic investigations. In the last few years, we have seen a rise in the availability of dedicated combined cardiac positron emission tomography scanners which combine molecular information from positron emission tomography with the fine anatomic detail provided by computed tomography or magnetic resonance imaging, which has in turn triggered a growing interest in the development of novel tracers providing new insight into biological disease processes. 18F-Sodium fluoride is a marker of active inflammation and calcification, and has shown promise as a novel radiotracer in cardiac imaging, having been applied in the assessment of a range of cardiac pathologies including atherosclerosis, valvular disease and cardiomyopathy.
MD and DEN are supported by the British Heart Foundation (CH/09/002, RE/18/5/34216) and a Wellcome Trust Senior Investigator Award (WT103782AIA).
- 11.Corrigendum to: 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2018;39:1980–1980.Google Scholar
- 18.Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2017;20:117–9.Google Scholar